Trials / Completed
CompletedNCT05520138
Enzalutamide vs. Abiraterone in Chemotherapy-naïve Metastatic Castration-resistant Prostate Cancer (mCRPC)
A Real-World Comparison of Clinical Outcomes in Chemotherapy-naive Metastatic Castration-resistant Prostate Cancer (mCRPC) Patients Who Initiated Enzalutamide vs. Abiraterone Acetate (Abiraterone) in the 100% Medicare Fee-For-Service (FFS) Data (2009-2020)
- Status
- Completed
- Phase
- —
- Study type
- Observational
- Enrollment
- 5,506 (actual)
- Sponsor
- Pfizer · Industry
- Sex
- Male
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
This study will be a retrospective data analysis to compare outcomes between patients with chemotherapy-naïve metastatic castration-resistant prostate cancer (mCRPC) who initiated enzalutamide and those who initiated abiraterone using the 100% Fee-For-Service Medicare claims data. The study will address the following objectives: Primary objective: To compare overall survival (OS) in patients with chemotherapy-naïve mCRPC who initiated enzalutamide vs. abiraterone Secondary objectives: * To compare OS in patients with chemotherapy-naïve mCRPC who received only enzalutamide without any subsequent therapy vs. abiraterone without any subsequent therapy * To compare treatment duration and time to subsequent therapy in chemotherapy-naïve mCRPC patients initiating enzalutamide vs. abiraterone
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Enzalutamide | As provided in real-world setting |
| DRUG | Abiraterone acetate | As provided in real-world setting |
Timeline
- Start date
- 2022-08-29
- Primary completion
- 2023-06-30
- Completion
- 2023-06-30
- First posted
- 2022-08-29
- Last updated
- 2024-09-27
- Results posted
- 2024-09-27
Locations
1 site across 1 country: United States
Source: ClinicalTrials.gov record NCT05520138. Inclusion in this directory is not an endorsement.